DermTech/DMTK

$0.62

-2.62%
-
1D1W1MYTD1YMAX

About DermTech

DermTech, Inc. is a molecular diagnostic company. The Company is engaged in developing and marketing non-invasive genomics tests to aid in the diagnosis and management of melanoma. Its technology enhances evaluation of lesions suspicious for melanoma using non-invasive sample collection and detecting genomic markers associated with melanoma to identify higher risk lesions or rule out melanoma with a 99% or higher negative predictive value (NPV). It offers DermTech Melanoma Test (the DMT), which is a non-invasive way to enhance evaluation of pigmented lesions suspicious for melanoma. Its genomics platform has been designed to work with its Smart Sticker, which provides an easy and non-invasive way to collect a skin sample, in contrast to the existing standard of care of using a scalpel to biopsy suspicious lesions. It also provides its research services and technology platform on a contract basis to pharmaceutical companies that use the technology to support their clinical trials.

Ticker

DMTK

Sector

Healthcare

Trading on

NASDAQ

Industry

Business Services

CEO

Bret Christensen

Employees

206

Headquarters

San diego, United States

Website

-

DermTech Metrics

BasicAdvanced
$21.54M
Market cap
-
P/E ratio
-$3.13
EPS
2.54
Beta
-
Dividend rate
$21.54M
2.54407
$4.67
$0.61
306.59K
4.592
4.518
0.066
0.096
-62.28%
-106.46%
-68.42%
1.408
0.376
0.377
5.36%
19.39%
37.49%

What the Analysts think about DermTech

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 4 analysts.
343.55% upside
High $4.00
Low $1.50
$0.62
Current price
$2.75
Average price target

DermTech Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-487.17% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$3.9M
0%
Net income
$-19M
-0.52%
Profit margin
-487.17%
-0.52%

DermTech Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 0.88%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$1.02
-$0.99
-$0.57
-$0.56
-
Expected
-$0.91
-$0.97
-$0.76
-$0.57
-$0.57
Surprise
12.44%
1.71%
-24.84%
-0.88%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for DermTech stock?

DermTech (DMTK) has a market cap of $21.54M as of April 14, 2024.

What is the P/E ratio for DermTech stock?

The price to earnings (P/E) ratio for DermTech (DMTK) stock is 0 as of April 14, 2024.

Does DermTech stock pay dividends?

No, DermTech (DMTK) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next DermTech dividend payment date?

DermTech (DMTK) stock does not pay dividends to its shareholders.

What is the beta indicator for DermTech?

DermTech (DMTK) has a beta rating of 2.54. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the DermTech stock price target?

The target price for DermTech (DMTK) stock is $2.75, which is 343.55% above the current price of $0.62. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell DermTech stock

Buy or sell DermTech stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing